RxDoctor Payments Data

Marcia Canto, MD

Gastroenterology · Baltimore, MDNPI 1992763015

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $5,258 of the $7,181 with a category attached, or 73.2%. 24 manufacturers reported payments, led by Pentax Of America, Inc. at 50.4% of the total. Reporting peaked in 2024 at $3,409 and has fallen 86.4% since, to $465 in 2025.

$7,181in general payments, 2019–2025

Across 97 payments — averaging $74.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pentax Of America, Inc.$4K
  • Medtronic$950
  • Cook Medical LLC$610
  • Endogastric Solutions, Inc$397
  • Fujifilm Healthcare Americas Corporation$291
  • AbbVie$260
  • plus $1K from 18 others
$1,578,146in research payments, 2019–2025

Across 47 payments — averaging $33,578 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Endogastric Solutions, Inc$941K
  • Pentax Of America, Inc.$558K
  • Lucid Diagnostics Inc.$79K

What the payments were for

  • Consulting fees$1,12516%
  • Speaking & faculty fees$74010%
  • Food & beverage$5,25873%
  • Gifts$581%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,181 in reported general payments places this provider in the 75th percentile of 455 gastroenterology providers in Maryland.

See all gastroenterology providers in Maryland

Medicare billing

Part B allowed, 2024
$132,241
Medicare patients
402
Services billed
3,339

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Esomeprazole Magnesium135$9,072
Sucralfate88$5,592
Omeprazole175$4,459
Famotidine279$3,878
Pantoprazole Sodium124$2,962
Rabeprazole Sodium16$1,104
Peg 3350-ElectrolyteSodium Chloride/Nahco3/Kcl/Peg29$642
Celecoxib12$177

Paid to pharmacies, not to this prescriber.

Other gastroenterology in Baltimore

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →